Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol.
Morris CA, Pokorny R, Lopez-Lazaro L, Miller RM, Arbe-Barnes S, Duparc S, Borghini-Fuhrer I, Shin JS, Fleckenstein L. Morris CA, et al. Among authors: arbe barnes s. Antimicrob Agents Chemother. 2014 Oct;58(10):5900-8. doi: 10.1128/AAC.02716-14. Epub 2014 Jul 28. Antimicrob Agents Chemother. 2014. PMID: 25070091 Free PMC article. Clinical Trial.
Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.
Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, Bustos DG, Tjitra E, Bedu-Addo G, Borghini-Fuhrer I, Duparc S, Shin CS, Fleckenstein L; Pyronaridine-artesunate Study Team. Tshefu AK, et al. Lancet. 2010 Apr 24;375(9724):1457-67. doi: 10.1016/S0140-6736(10)60322-4. Lancet. 2010. PMID: 20417857 Clinical Trial.
First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials.
Moehrle JJ, Duparc S, Siethoff C, van Giersbergen PL, Craft JC, Arbe-Barnes S, Charman SA, Gutierrez M, Wittlin S, Vennerstrom JL. Moehrle JJ, et al. Br J Clin Pharmacol. 2013 Feb;75(2):524-37. doi: 10.1111/j.1365-2125.2012.04368.x. Br J Clin Pharmacol. 2013. PMID: 22759078 Free PMC article. Clinical Trial.
Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial.
Dabira ED, Hachizovu S, Conteh B, Mendy A, Nyang H, Lawal B, Ndiath MO, Mulenga JM, Mwanza S, Borghini-Fuhrer I, Arbe-Barnes S, Miller R, Shin J, Duparc S, D'Alessandro U, Manyando C, Achan J. Dabira ED, et al. Among authors: arbe barnes s. Clin Infect Dis. 2022 Jan 29;74(2):180-188. doi: 10.1093/cid/ciab425. Clin Infect Dis. 2022. PMID: 33983371 Free PMC article. Clinical Trial.
Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study.
Tona Lutete G, Mombo-Ngoma G, Assi SB, Bigoga JD, Koukouikila-Koussounda F, Ntamabyaliro NY, Ntoumi F, Agnandji ST, Groger M, Shin J, Borghini-Fuhrer I, Arbe-Barnes S, Allen SJ, Kremsner PG, Miller R, Duparc S, Ramharter M; CANTAM study group. Tona Lutete G, et al. Among authors: arbe barnes s. PLoS Med. 2021 Jun 15;18(6):e1003669. doi: 10.1371/journal.pmed.1003669. eCollection 2021 Jun. PLoS Med. 2021. PMID: 34129601 Free PMC article.
Effectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial.
Groger M, Tona Lutete G, Mombo-Ngoma G, Ntamabyaliro NY, Kahunu Mesia G, Muena Mujobu TB, Dimessa Mbadinga LB, Zoleko Manego R, Egger-Adam D, Borghini-Fuhrer I, Shin J, Miller R, Arbe-Barnes S, Duparc S, Ramharter M. Groger M, et al. Among authors: arbe barnes s. Lancet Microbe. 2022 Aug;3(8):e598-e605. doi: 10.1016/S2666-5247(22)00092-1. Epub 2022 May 30. Lancet Microbe. 2022. PMID: 35654079 Free PMC article. Clinical Trial.
Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial.
Chandiwana N, Kruger C, Johnstone H, Chughlay MF, Ju C, Kim B, Dineka Y, Arbe-Barnes S, Miller R, Owen A, Hill A, Windgassen D, Abla N, Marrast AC, Duparc S, Francois Venter WD. Chandiwana N, et al. Among authors: arbe barnes s. EBioMedicine. 2022 Dec;86:104322. doi: 10.1016/j.ebiom.2022.104322. Epub 2022 Nov 1. EBioMedicine. 2022. PMID: 36332361 Free PMC article. Clinical Trial.
Community health workers in clinical research at the example of a phase IIIb/ IV antimalarial drug trial conducted in five African countries.
Groger M, Lutete GT, Assi SB, Bigoga JD, Ntamabyaliro NY, Arbe-Barnes S, Shin J, Adegnika AA, Ntoumi F, Kremsner PG, Ramharter M, Duparc S, Borghini-Fuhrer I, Mombo-Ngoma G. Groger M, et al. Among authors: arbe barnes s. Int J Infect Dis. 2023 Dec;137:114-117. doi: 10.1016/j.ijid.2023.10.016. Epub 2023 Oct 21. Int J Infect Dis. 2023. PMID: 37871675 Free PMC article. Clinical Trial.
16 results